The Business Advisory Board is composed of leaders in the life-sciences and finance world with experience in the pharmaceutical, biotechnology, medical device, investment banking, venture capital and financial management industries. The BAB members assess grant and investment opportunities and provide advice and direction to support the commercialization of new therapies. The BAB members also work with the SAB and the Board in setting strategic direction to guide the organization and our programs.
Co-Chairs
- Stephen D. Collins MD, PhD
President, CEO & Director
Insero Health, Inc. - Garry E. Menzel PhD, MBA
Chief Business and Strategy Officer
Pronutria Biosciences
Members
- Karen L. Bergman
Founder and Principal
BCC Partners - Thomas A. Bologna
President & CEO
Orchid Cellmark, Inc. - Frank Fischer
President & CEO
NeuroPace, Inc. - Jeffrey D. Glidden
Executive Vice President & CFO
Parametric Technology Corporation - Nina Graves PharmD
Retired (Former) Epilepsy Program Director
Medtronic Inc. - Warren Lammert
Founder, Managing Partner
Granite Point Capital - Lisa Lindahl
Chief Executive Instigator at EZL Enterprises
Co-founder and Partner at Bellisse - Heath Lukatch PhD
Partner
Novo Ventures - Daniel J. O'Connell
Director
NeuroVentures Capital LLC - Sherrie Perkins
Senior Director New Business Development
Cyberonics, Inc. - David A. Sadock
President & CEO
Ethos Health Communications - Aaron Sandoski
Managing Director
Norwich Ventures - Nancy Santilli BSN, MSN
Vice President, Commercial Strategy and Portfolio Planning
Endo Pharmaceuticals, Inc. - Ned Scheetz
Managing Director
Aphelion Capital, LLC - Randy Siegel
President, Local Digital Strategy
Advance Publications, Inc. - Lauren Silverman PhD
Managing Director
Novartis Option Fund - Matthew Simonian
Senior Director, Epilepsy Marketing
Cyberonics, Inc. - Reese S. Terry, Jr.
Founder
Cyberonics, Inc. - Elizabeth S. Weiswasser
Litigation Partner
Weil, Gotshal & Manges LLP - Gregory T. Went PhD
CEO and Chairman
Adamas Pharmaceuticals, Inc.
